S-4 7.64 (d, J = 3.9 Hz, 1H); 13 C NMR (75 MHz, 34.5, 35.1, 52.4, 52.5, 74.0, 82.4, 125.3, 128.5, 128.7, 130.0, 133.3, 133.5, 134.2, 134.6, 135.0, 135.4, 135.4, 138.9, 141.8, 143.0, 161.4 
Compound 4
Compound 2 (0.965 g, 1.68 mmol) was dissolved in DMF (10 mL) and the solution was cooled to -15 °C. NBS (0.210 g, 1.18 mmol) was added portion wise during one min. The solution was allowed to attain RT during 2 h, again cooled to -15 °C, more NBS (0.095 g, 0.534 mmol) was added portion wise during one min, and the solution was allowed to attain RT. Dilution with EtOAc, washing with brine, drying, filtering, concentration, and FC (toluene, toluene/EtOAc 60:1➝9:1) gave 4 (1.020 g, 93%) as a yellow solid. 1 4, 34.6, 34.9, 52.5, 82.1, 111.9, 124.2, 127.7, 128.1, 128.2, 131.3, 131.5, 133.1, 133.1, 133.6, 134.3, 134.4, 134.9, 135.6, 135.7, 142.6, 161.4, 170.9, 171.0 
Compound 5
Compound 3 (0.080 g, 0.114 mmol) and CuCN (0.100 g, 1.12 mmol) were transferred to a microwave vial and DMF (2 mL) was added. Microwave irradiation at 170 °C for 15 min was followed by addition of EtOAc and washing with saturated NaHCO3 (aq) and water. Purification by HPLC (C-18, 80-100% eluent B in eluent D in a linear gradient over 10 min followed by isocratic 100% eluent B for 15 min) gave 5 (0.023 g, 34%) as an orange solid. 1 3, 34.3, 34.8, 52.4, 52.5, 77.5, 108.2, 113.7, 124.2, 127.8, 128.1, S-5 129. 2, 130.9, 131.9, 132.2, 133.1, 133.5, 134.5, 135.9, 137.3, 139.9, 140.3, 142 
q-FTAA-CN
To a solution of 5 (0.023 g, 0.038 mmol) in DCM (2 mL) was added TFA (0.5 mL) and the solution was stirred for 2 h and co-concentrated with toluene. To the residual in dioxane (3 mL) at 0 °C was added 1M NaOH (aq) (0.100 mL, 0.100 mmol) and water (1 mL). The reaction mixture was stirred at 0 °C for 30 min and for an additional 4 h at RT. Subsequent (without workup) purification by HPLC (C-8, 0-70% eluent C in eluent E in a linear gradient over 15 min followed by isocratic 100% eluent C for 10 min) gave q-FTAA-CN (0.011 g, 56%) as an orange solid as a TEA-salt. To the solid was added 1M NaOH (aq) (0.070 mL, 0.070 mmol) and water until everything went into solution. 128.5, 129.4, 130.2, 131.9, 132.4, 134.3, 136.0, 136.1, 136.8, 138.7, 140.7, 141.3, 142.1, 143.3, 169.3, 177.1; -calcd for C22H12NO6S4 -513.9547].
q-FTAA-Br
To a solution of 4 (0.126 g, 0.206 mmol) in DCM (3 mL) was added trifluoroacetic acid (1 mL) and the solution was stirred for 2 h and co-concentrated with toluene. To the residual in dioxane (3 mL) was added 1M NaOH aq. (0.927 mL, 0.927 mmol) and water (1 mL 2, 38.4, 110.3, 124.4, 126.4, 126.5, 129.1, 131.9, 132.1, 133.7, 134.0, 134.4, 134.5, 134.6, 135.4, 139.6, 140.9, 169.8, 179.2, 179 4, 34.8, 34.9, 52.5, 52.6, 82.2, 108.1, 114.2, 123.8, 124.2, 127.9, 128.2, 128.2, 129.2, 131.6, 131.7, 132.9, 133.6, 134.4, 134.5, 135.0, 135.7, 136.1, 138.4, 142.5, 143.9, 161.3, 170.9 
p-FTAA-CN
To a solution of 6 (0.020 g, 0.029 mmol) in DCM (2 mL) was added trifluoroacetic acid (0.5 mL) and the solution was stirred for 2 h and co-concentrated with toluene. To the residual in dioxane (3 mL) at 0 °C was added 1M NaOH (aq) (0.132 mL, 0.132 mmol) and water (1 mL).
The reaction mixture was stirred at 0 °C for 30 min and for an additional 4 h at RT. Subsequent S-7 (without workup) purification by HPLC (C-8, 0-70% eluent C in eluent E in a linear gradient over 15 min followed by isocratic 100% eluent C for 10 min) gave p-FTAA-CN (0.010 g, 58%)
as an orange solid. To the solid was added 1M NaOH (aq) (0.055 mL, 0.055 mmol) and water until everything went into solution. 6, 115.6, 124.7, 125.0, 127.7, 128.2, 129.5, 131.3, 132.2, 132.4, 133.1, 134.3, 135.7, 135.7, 135.9, 136.9, 140.8, 141.4, 141.5, 145.7, 170.0, 178.7 4, 52.5, 82.1, 124.1, 124.2, 125.1, 126.9, 127.5, 127.8, 128.0, 128.2, 131.2, 131.3, 131.5, 133.3, 133.6, 134.3, 135.1, 135.4, 136.0, 136.5, 136.7, 142.6, 161.3, 171.0 52.5, 82.3, 111.3, 125.4, 125.7, 128.1, 128.3, 128.9,130.3, 131.3, 132.3, 132.6, 132.8, 133,5, 133.9, 134.1, 134.7, 134.8, 135.1, 137.6,142.1, 160.7, 170,8, 170.9 
p-FTAA-Br
To a solution of 8 (0.047 g, 0.064 mmol) in DCM (3 mL) was added TFA (1 mL) and the solution was stirred for 2 h and co-concentrated with toluene. To the residual in dioxane (1 mL) was added 1M NaOH (aq) (0.288 mL, 0.288 mmol) and water (0.5 mL). 125. 1, 127.5, 127.7, 128.6, 130.0, 130.7, 131.8, 132.0, 133.0, 133.1, 133.5, 133.5, 133.9, 134.4, 134.4, 134.8, 137.3, 141.8, 162.6, 171.5 
Compound 10
To a solution of 9 (0.101 g, 0.144 mmol), 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-ethanol (0.060 g, 0.31 mmol), and DIPEA (0.101 mL, 0.580 mmol) in DMF (3 mL) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetra-methyluronium hexafluoro-phosphate (HATU) (0.085 g, 0.22 mmol). After 2 h EtOAc and brine were added and the organic phase was separated and washed with saturated NH4Cl (aq), saturated NaHCO3 (aq) and water, dried, filtered and concentrated. Purification by gradient HPLC (C-18, 60-100% eluent A in eluent D in a linear gradient over 15 min followed by isocratic 100% eluent A for 10 min) gave compound 10 3, 34.8, 34.8, 39.9, 52.4, 61.6, 70.0, 70.2, 70.5, 70.6, 72.6, 82.1, 124.1, 127.7, 127.7, 127.9, 128.1, 128.8, 131.4, 132.7, 133.1, 133.6, 134.2, 135.4, 135.4, 135.6, 135.7, 138.5, 140.8, 142.5, 161.3, 161.9 
Compound 12
Compound 11 (0.232 g, 1.05 mmol) was dissolved in MeOH (3 mL). PPh3 (0.550 g, 2.10 mmol) and H2O (0.1 mL) were added and the mixture was stirred at 50 °C for 2 h and 
Compound 13
To a stirred solution of 9 (0.054 g, 0.077 mmol), 12 (0.030 g, 0.154 mmol), and DIPEA (0.050 mL, 0.287 mmol) in DMF (3 mL) was added O- (7-azabenzotriazol-1-yl)-N,N,N',N'-tetra- 4, 34.9, 39.9, 52.5, 69.9, 70.4, 70.7, 70.7, 70.8, 71.0, 83.2 (d, JCF = 169.3 Hz), 124.2, 124.2, 127.8, 128.1, 128.2, 128.8, 131.5, 132.9, 133.1, 133.6, 134 .3.
p-FTAA-TEG-F
Protetected p-FTAA-TEG-F (0.008 g, 0.009 mmol) was dissolved in DCM (1 mL) and trifluoroacetic acid (0.333 mL) was added. The reaction mixture was stirred for 2 h and coconcentrated with toluene. To the residual in dioxane (1 mL) at 0 °C was added 1M NaOH (aq) 39.3, 68.6, 69.4, 69.5, 69.7, 69.8, 70.0, 83.3 (d, JCF = 163.3 Hz), 124.1, 126.0, 126.2, 129.0, 129.4, 130.4, 131.7, 131.9, 132.4, 133.1, 133.8, 134.1, 134.6, 134.9, 135.1, 139.5, 140.8, 141.8, 163.4, 169.3, 178.7, 178.8 
p-FTAM-tBu-TEG-OTs
To a solution of 10 (0.088 g, 0.100 mmol) in dry CHCl3 (3 mL) were added p-toluenesulphonyl chloride (0.056 g, 0.294 mmol) and pyridine (1 mL). After 4 h the solution was diluted with S-14 Ethanol, and 5 minutes respectively in 80% Ethanol, 60% Ethanol, 40% Ethanol. After rehydration with deionized water, the sections were incubated with PBS for 10 min and then stained for 30 min at RT with reference compounds q-FTAA-CN, p-FTAA-CN and p-FTAA-TEG-F. All probes were diluted 1:500 in PBS from a 1.5 mM stock. After rinsing with PBS three times, the sections were mounted with Dako fluorescence mounting medium (Dako Cytomation, Glostrup, Denmark). The medium was allowed to solidify for three hours before the rims were sealed with nail polish. Fluorescence images were collected with an inverted LSM 780 confocal microscope (Carl Zeiss, Oberkochen, Germany) using single excitation wavelength at 458 nm.
Homogenate Binding
Tissues ( Figure S1 ). Different blood samples are taken throughout the study ( Figure S2 ): i) A 115 L venous sample was taken at the induction of anaesthesia and at the middle and end of experiment for estimation of blood gases, electrolytes, hematocrite and glucose. ii) Blood samples (0.2 mL) for radioactivity determination were taken at 0.5, 1, 3, 5, 10, 15, 20, 30, 45 S-16 and 60 min after each injection. iii). Three blood samples comprise 0.5 mL, which were centrifuged after radioactive measurement and the plasma was transferred to a new vial for measurement of plasma concentration of radioactivity. Figure S1 . Time activity SUV curves of the uptake in the brain of the three ligands in a female Cynomolgus monkey as measured using PET. Figure S2 . Time activity SUV curves of the uptake in the blood of the three ligands.
